By Fineline Cube 
Jacobio Pharma Ltd. (HKG: 1167) announced today that its subsidiary Beijing Jacobio Pharmaceuticals Co., Ltd. has entered into a capital‑increase and equity‑transfer agreement, granting Oceanpine Capital an 80 % stake in the project company Jacoray for a total of RMB 200 million (RMB 125 million upfront plus a RMB 75 million milestone payment). The remaining 20 % will be split equally between Beijing Jacobio and an undisclosed industry partner, creating a 10/80/10 ownership structure.
Transaction Structure
- Equity Allocation – 10 % retained by Beijing Jacobio, 80 % acquired by Oceanpine Capital, 10 % held by the industry partner.
- Consideration – RMB 125 million paid immediately, RMB 75 million payable upon achievement of agreed R&D milestones.
- Capital Use – Proceeds earmarked for research, manufacturing, and commercialization of Jacobio’s Pan‑KRAS inhibitor and other oncology assets.
Strategic Rationale
- Focus Shift – Jacobio is concentrating on oncology breakthroughs (KRAS, iADC) while divesting its cardiovascular research vehicle.
- Capital Efficiency – The deal optimizes capital allocation and leverages Oceanpine Capital’s experience in scaling biotech platforms.
- Risk‑Sharing Model – Joint ownership reduces financial exposure while preserving long‑term project value.
Forward‑Looking Statements
This release includes forward‑looking statements subject to risks and uncertainties that could cause actual results to differ materially.-Fineline Info & Tech